Immunic Inc To Discuss Interim Data Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive MS Call Transcript
Good morning to our audience today. I would like to welcome you to Immunic's webcast to present the positive interim data from our Phase II CALLIPER trial of vidofludimus calcium in patients with progressive multiple sclerosis, reported after the market closed yesterday.
My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's webcast. Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer and President; and Dr. Andreas Muehler, our Chief Medical Officer. (Operator Instructions) And this event is being recorded. After today's presentation, there will be an opportunity to ask questions. (Operator Instructions).
Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate or words with similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunic's actual results to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
